Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15
MT NewswiresMar 19 22:44
Veradigm Analyst Ratings
BenzingaMar 19 17:59
Veradigm's Challenging Outlook: Hold Rating Justified Amid Revenue Growth, Margin Pressures, and Audit Concerns
TipRanksMar 19 16:35
Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)
TipRanksMar 16 09:50
Veradigm Analyst Ratings
BenzingaJan 19 22:05
RBC Halves Price Target on Veradigm to $11 From $22, Keeps Outperform Rating
MT NewswiresJan 19 21:12
Barclays Starts Allscripts Healthcare Solutions With Equalweight Rating, $11 Price Target
MT NewswiresJan 3 20:41
Barclays Initiates Coverage On Veradigm With Equal-Weight Rating, Announces Price Target of $11
BenzingaJan 3 18:32
Veradigm Analyst Ratings
BenzingaJan 3 18:31
Deutsche Bank Adjusts Veradigm Price Target to $15 From $18, Maintains Buy Rating
MT NewswiresDec 11, 2023 23:25
Stephens & Co. Reiterates Equal-Weight on Veradigm, Maintains $13 Price Target
BenzingaNov 14, 2023 21:23
Veradigm Analyst Ratings
BenzingaNov 14, 2023 21:21
Stephens & Co. Reiterates Equal-Weight on Veradigm, Maintains $13 Price Target
BenzingaOct 10, 2023 22:16
Veradigm Analyst Ratings
BenzingaOct 10, 2023 22:15
Research Alert: CFRA Drops Analytical Coverage Of Veradigm Inc.
MT NewswiresOct 10, 2023 22:15
RBC Capital Reaffirms Their Buy Rating on Veradigm (MDRX)
TipRanksJul 21, 2023 09:46
Stephens Initiates Allscripts Healthcare Solutions at Equalweight With $13 Price Target
MT NewswiresApr 12, 2023 19:17
Stephens & Co. Initiates Coverage On Veradigm With Equal-Weight Rating, Announces Price Target of $13
BenzingaApr 12, 2023 17:00
Piper Sandler Downgrades Veradigm to Neutral, Raises Price Target to $18.5
Benzinga Real-time NewsFeb 1, 2023 18:21
Allscripts Upgraded to Buy at Argus on Increasing Margins, Veradigm Business
Seeking AlphaDec 8, 2022 02:49
No Data
No Data